期刊
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
卷 49, 期 1, 页码 1-9出版社
JOHN WILEY & SONS LTD
DOI: 10.1002/jlcr.1017
关键词
quinolinone; Aripiprazole; carbon-14 synthesis
Development of Aripiprazole as an oral treatment of schizophrenia required the synthesis of a suitably labeled drug product for use in human metabolism and pharmacokinetic studies. Due to the potential metabolic degradation of the molecule, a multi-labeled approach utilizing C-14 was adopted. The synthesis of [C-14]Aripiprazole was accomplished in separate syntheses from 2,3-dichloro[U-C-14]aniline and [3-C-14]-cinnamic acid, respectively. Labeled versions were combined on the basis of molar radioactivity giving a final product with a radiochemical purity of 99.9% and a specific activity of 15.5 mu Ci/mg. Copyright (c) 2005 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据